公开(公告)号：US5939532A

公开(公告)日：1999-08-17

申请号：US483528

申请日：1995-06-07

申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

IPC分类号： C07K16/18 ,  C07K16/46 ,  C12P21/08 ,  C07K16/00 ,  C12N5/00 ,  C12P21/06

CPC分类号： C07K16/18 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00

摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

公开(公告)号：US08363944B2

公开(公告)日：2013-01-29

申请号：US12196964

申请日：2008-08-22

申请人： Masamichi Koike

发明人： Masamichi Koike

IPC分类号： G06K9/00

CPC分类号： G06F21/608 ,  G06F21/64

摘要： An information processing system includes a signature apparatus and a signature verification apparatus which may be provided separately. The signature apparatus includes a document image generating unit and a print image generating unit. The document image generating unit generates a document image to be signed including document image data and error correction data for character images contained in the document image data. The print image generating unit synthesizes the document image and a code image to generate a print image. The signature verification apparatus includes a restoring unit that restores, from a print image, document image data included in a document image to be signed, using error correction data contained in the document image, and a signature verification unit that performs signature verification using the restored document image data and document image data included in a document image to be signed extracted from the print image.

摘要翻译： 信息处理系统包括可以单独提供的签名装置和签名验证装置。 签名装置包括文件图像生成单元和打印图像生成单元。 文档图像生成单元生成包含文档图像数据的文档图像和包含在文档图像数据中的文字图像的纠错数据。 打印图像生成单元合成文档图像和代码图像以生成打印图像。 签名验证装置包括恢复单元，该恢复单元使用包含在文档图像中的纠错数据，从打印图像恢复要签名的文档图像中包括的文档图像数据，以及签名验证单元，其使用恢复的文件图像进行签名验证 从打印图像提取的要签名的文档图像中包括的文档图像数据和文档图像数据。

公开(公告)号：US20120177643A1

公开(公告)日：2012-07-12

申请号：US13428739

申请日：2012-03-23

申请人： Kenya Shitara ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Shimizu ,  Masamichi Koike

发明人： Kenya Shitara ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Shimizu ,  Masamichi Koike

IPC分类号： A61K39/395 ,  A61P37/00 ,  A61P35/02 ,  A61P37/08 ,  C12N5/0783 ,  A61P35/00

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K14/7158 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/57492 ,  G01N33/6863 ,  G01N2333/4719 ,  G01N2333/7158

摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

摘要翻译： 与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

公开(公告)号：US07504104B2

公开(公告)日：2009-03-17

申请号：US10231452

申请日：2002-08-30

申请人： Kenya Shitara ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Tanaka ,  Masamichi Koike

发明人： Kenya Shitara ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Tanaka ,  Masamichi Koike

IPC分类号： A61K39/395 ,  C12P21/08

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K14/7158 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/57492 ,  G01N33/6863 ,  G01N2333/4719 ,  G01N2333/7158

摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

摘要翻译： 与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

公开(公告)号：US20050272918A1

公开(公告)日：2005-12-08

申请号：US11193512

申请日：2005-08-01

申请人： Masamichi Koike ,  Akiko Furuya ,  Kazuyasu Nakamura ,  Akihiro Iida ,  Hideharu Anazawa ,  Nobuo Hanai ,  Kiyoshi Takatsu

发明人： Masamichi Koike ,  Akiko Furuya ,  Kazuyasu Nakamura ,  Akihiro Iida ,  Hideharu Anazawa ,  Nobuo Hanai ,  Kiyoshi Takatsu

IPC分类号： A61K38/00 ,  C07K14/715 ,  C07K16/24 ,  C07K16/28 ,  C12N5/18 ,  C12P21/08

CPC分类号： C07K16/2866 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/7155 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026

摘要： The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor α chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor α chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

摘要翻译： 本发明提供与人白细胞介素-5受体α链特异性反应的单克隆抗体和人源化抗体。 本发明还提供产生抗体的杂交瘤和转化体，单克隆抗体和人源化抗体，通过这些抗体免疫学检测白细胞介素-5受体α链的方法，以及用于诊断和治疗慢性疾病的方法 支气管哮喘通过单克隆抗体和人源化抗体。 本发明可用于诊断或治疗慢性支气管哮喘等疾病。

公开(公告)号：US20050226867A1

公开(公告)日：2005-10-13

申请号：US10959326

申请日：2004-10-07

申请人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara ,  Masamichi Koike

发明人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara ,  Masamichi Koike

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2866 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732

摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

摘要翻译： 本发明提供一种抗体组合物，其包含特异性结合人白细胞介素-5受体α链并在Fc区具有复合型N-糖苷连接的糖链的抗体分子，其中复合型N-糖苷连接的糖链具有 岩藻糖在糖链的还原端不与N-乙酰氨基葡萄糖结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

公开(公告)号：US5830470A

公开(公告)日：1998-11-03

申请号：US116778

申请日：1993-09-07

申请人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

发明人： Kazuyasu Nakamura ,  Masamichi Koike ,  Kenya Shitara ,  Nobuo Hanai ,  Yoshihisa Kuwana ,  Mamoru Hasegawa

IPC分类号： A61K38/00 ,  C07K16/18 ,  C07K16/46 ,  C12N1/21 ,  C12N15/13 ,  C12P21/08 ,  A61K39/395 ,  C07H21/04 ,  C12P21/04

CPC分类号： C07K16/3084 ,  C07K16/18 ,  C07K16/464 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/00 ,  C07K2319/035 ,  Y10S530/867

摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

公开(公告)号：US08501176B2

公开(公告)日：2013-08-06

申请号：US13177221

申请日：2011-07-06

申请人： Masamichi Koike ,  George L. Spitalny ,  Alistair Wheeler ,  Barbara White

发明人： Masamichi Koike ,  George L. Spitalny ,  Alistair Wheeler ,  Barbara White

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K7/08 ,  C07K16/2866 ,  C07K2317/24

摘要： The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.

摘要翻译： 本发明涉及一种减少人受试者嗜酸性粒细胞数量的方法，包括向受试者施用包含（a）特异性结合IL-5R的区域和（b）免疫球蛋白Fc的IL-5R结合分子 地区。 在具体实施方案中，本发明的方法减少血液，骨髓，胃肠道（例如食道，胃，小肠和结肠）或肺中嗜酸性粒细胞的数量。

公开(公告)号：US08143058B2

公开(公告)日：2012-03-27

申请号：US12903780

申请日：2010-10-13

申请人： Kenya Shitara ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Shimizu ,  Masamichi Koike

发明人： Kenya Shitara ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Shimizu ,  Masamichi Koike

IPC分类号： C12N5/16

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K14/7158 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/57492 ,  G01N33/6863 ,  G01N2333/4719 ,  G01N2333/7158

摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

摘要翻译： 与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。

公开(公告)号：US20110059524A1

公开(公告)日：2011-03-10

申请号：US12903780

申请日：2010-10-13

申请人： Kenya SHITARA ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Shimizu ,  Masamichi Koike

发明人： Kenya SHITARA ,  Kazuyasu Nakamura ,  Emi Hosaka ,  Akiko Shimizu ,  Masamichi Koike

IPC分类号： C12N5/10

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K14/7158 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  G01N33/57492 ,  G01N33/6863 ,  G01N2333/4719 ,  G01N2333/7158

摘要： A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

摘要翻译： 与人CC趋化因子受体4（CCR4）的细胞外区特异性反应但不与人血小板反应的人CDR-移植抗体或其抗体片段; 与CCR4的胞外区特异性反应并对CCR4表达细胞具有细胞毒活性的人CDR-移植抗体或其抗体片段; 以及包含至少一种抗体及其抗体片段作为活性成分的药物，治疗剂或诊断剂。